Antonio Uccelli

List of Publications by Year
in descending order

240 papers	20,750 citations	17405 63 h-index	11030 137 g-index
251 all docs	251 docs citations	251 times ranked	22328 citing authors

#	Article	IF	Citations
1	Mesenchymal stem cells in health and disease. Nature Reviews Immunology, 2008, 8, 726-736.	10.6	3,028
2	Human mesenchymal stem cells modulate B-cell functions. Blood, 2006, 107, 367-372.	0.6	1,583
3	Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood, 2005, 106, 1755-1761.	0.6	1,318
4	C-C chemokine receptor 6â€“regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nature Immunology, 2009, 10, 514-523.	7.0	1,030
5	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	6.3	684
6	Immunoregulatory function of mesenchymal stem cells. European Journal of Immunology, 2006, 36, 2566-2573.	1.6	490
7	Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Annals of Neurology, 2007, 61, 219-227.	2.8	450
8	Mesenchymal stem cells: a new strategy for immunosuppression?. Trends in Immunology, 2007, 28, 219-226.	2.9	424
9	Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11064-11069.	3.3	322
10	Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Human Molecular Genetics, 2006, 15, 2813-2824.	1.4	279
11	Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurology, The, 2011, 10, 649-656.	4.9	279
12	The prevalence of pain in multiple sclerosis. Neurology, 2004, 63, 919-921.	1.5	274
13	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	1.4	249
14	Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17384-17389.	3.3	241
15	Human Mesenchymal Stem Cells Promote Survival of T Cells in a Quiescent State. Stem Cells, 2007, 25, 1753-1760.	1.4	231
16	The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Multiple Sclerosis Journal, 2010, 16, 503-510.	1.4	212
17	Neuroprotective features of mesenchymal stem cells. Best Practice and Research in Clinical Haematology, 2011, 24, 59-64.	0.7	195
18	Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine, 2021, 72, 103581.	2.7	184

#	Article	IF	Citations
19	Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 3601-3605.	3.3	173
20	Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. Journal of Neurochemistry, 2009, 110, 1674-1684.	2.1	169
21	The immunomodulatory function of mesenchymal stem cells: mode of action and pathways. Annals of the New York Academy of Sciences, 2015, 1351, 114-126.	1.8	164
22	Interferonâ€Î³â€“dependent inhibition of B cell activation by bone marrowâ€“derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis and Rheumatism, 2010, 62, 2776-2786.	6.7	161
23	Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathologica, 2015, 130, 279-295.	3.9	160
24	Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. Journal of Leukocyte Biology, 2003, 73, 584-590.	1.5	159
25	Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application. Haematologica, 2008, 93, 339-346.	1.7	159
26	Tâ€cell trafficking in the central nervous system. Immunological Reviews, 2012, 248, 216-227.	2.8	157
27	Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Research and Therapy, 2007, 9, 301.	1.6	150
28	Reciprocal Interactions Between Human Mesenchymal Stem Cells and Î³Î´ T Cells Or Invariant Natural Killer T Cells. Stem Cells, 2009, 27, 693-702.	1.4	150
29	Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE. PLoS ONE, 2009, 4, e7897.	1.1	143
30	Cell-based therapeutic strategies for multiple sclerosis. Brain, 2017, 140, 2776-2796.	3.7	139
31	COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?. Multiple Sclerosis and Related Disorders, 2020, 42, 102120.	0.9	138
32	Intravenous Mesenchymal Stem Cells Improve Survival and Motor Function in Experimental Amyotrophic Lateral Sclerosis. Molecular Medicine, 2012, 18, 794-804.	1.9	135
33	Autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurology, 2017, 88, 2115-2122.	1.5	134
34	Mesenchymal Stem Cells Shape Microglia Effector Functions Through the Release of CX3CL1. Stem Cells, 2012, 30, 2044-2053.	1.4	127
35	Why should mesenchymal stem cells (MSCs) cure autoimmune diseases?. Current Opinion in Immunology, 2010, 22, 768-774.	2.4	124
36	Myelin/Oligodendrocyte Glycoprotein-Induced Autoimmune Encephalomyelitis in Common Marmosets: The Encephalitogenic T Cell Epitope pMOG24â€“36 Is Presented by a Monomorphic MHC Class II Molecule. Journal of Immunology, 2000, 165, 1093-1101.	0.4	123

#	Article	IF	Citations
37	Role of B Cells in Multiple Sclerosis and Related Disorders. Annals of Neurology, 2021, 89, 13-23.	2.8	123
38	Detrimental and protective action of microglial extracellular vesicles on myelin lesions: astrocyte involvement in remyelination failure. Acta Neuropathologica, 2019, 138, 987-1012.	3.9	120
39	An open-lebel trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology, 1998, 51, 609-611.	1.5	119
40	Î±-Lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2004, 148, 146-153.	1.1	118
41	Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Multiple Sclerosis Journal, 2012, 18, 835-842.	1.4	115
42	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2019, 18, 845-856.	4.9	110
43	Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain, 2003, 126, 285-291.	3.7	109
44	Low-Dose Gabapentin Combined with either Lamotrigine or Carbamazepine Can Be Useful Therapies for Trigeminal Neuralgia in Multiple Sclerosis. European Neurology, 2000, 44, 45-48.	0.6	108
45	Surrogate endpoints for EDSS worsening in multiple sclerosis. Neurology, 2010, 75, 302-309.	1.5	103
46	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e823-e831.	1.5	102
47	Isolated cognitive relapses in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1035-1037.	0.9	101
48	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. Multiple Sclerosis Journal, 2018, 24, 590-603.	1.4	101
49	Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. Bone Marrow Transplantation, 2009, 43, 821-828.	1.3	99
50	Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology, 1998, 50, 1127-1133.	1.5	98
51	Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis. Journal of Autoimmunity, 2016, 72, 8-18.	3.0	95
52	Regulatory Functions of Natural Killer Cells in Multiple Sclerosis. Frontiers in Immunology, 2016, 7, 606.	2.2	88
53	Unveiling the enigma of the CNS as a B-cell fostering environment. Trends in Immunology, 2005, 26, 254-259.	2.9	87
54	Demyelination and axonal damage in a non-human primate model of multiple sclerosis. Journal of the Neurological Sciences, 2001, 184, 41-49.	0.3	74

#	Article	IF	Citations
55	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e832-e839.	1.5	74
56	Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. Multiple Sclerosis Journal, 2005, 11, 367-371.	1.4	73
57	Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism. Stem Cells Translational Medicine, 2016, 5, 1506-1514.	1.6	73
58	Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Multiple Sclerosis Journal, 2008, 14, 1225-1233.	1.4	72
59	Local-clonal expansion of infiltrating T lymphocytes in chronic encephalitis of Rasmussen. Journal of Immunology, 1997, 158, 1428-37.	0.4	70
60	Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients. Journal of NeuroImmune Pharmacology, 2013, 8, 1106-1113.	2.1	69
61	Role of miRNAs shuttled by mesenchymal stem cell-derived small extracellular vesicles in modulating neuroinflammation. Scientific Reports, 2021, 11, 1740.	1.6	69
62	The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms. Stem Cell Research and Therapy, 2012, 3, 3.	2.4	68
63	Can we switch microglia's phenotype to foster neuroprotection? Focus on multiple sclerosis. Immunology, 2014, 141, 328-339.	2.0	67
64	Immunometabolic profiling of T cells from patients with relapsing-remitting multiple sclerosis reveals an impairment in glycolysis and mitochondrial respiration. Metabolism: Clinical and Experimental, 2017, 77, 39-46.	1.5	67
65	The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction. Patient Preference and Adherence, 2017, Volume 11, 33-45.	0.8	65
66	Blood-Brain Barrier Alterations in the Cerebral Cortex in Experimental Autoimmune Encephalomyelitis. Journal of Neuropathology and Experimental Neurology, 2012, 71, 840-854.	0.9	64
67	X-Ray Phase Contrast Tomography Reveals Early Vascular Alterations and Neuronal Loss in a Multiple Sclerosis Model. Scientific Reports, 2017, 7, 5890.	1.6	64
68	Stem cells in inflammatory demyelinating disorders: a dual role for immunosuppression and neuroprotection. Expert Opinion on Biological Therapy, 2006, 6, 17-22.	1.4	63
69	Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimerâ€™s mice. Cell Death and Differentiation, 2021, 28, 203-218.	5.0	63
70	Mesenchymal stem cells as treatment for MS â€“ progress to date. Multiple Sclerosis Journal, 2013, 19, 515-519.	1.4	62
71	The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse. BMC Genomics, 2007, 8, 65.	1.2	61
72	Mesenchymal stem cells for the treatment of neurological diseases: Immunoregulation beyond neuroprotection. Immunology Letters, 2015, 168, 183-190.	1.1	59

#	Article	IF	Citations
73	The Italian multiple sclerosis register. Neurological Sciences, 2019, 40, 155-165.	0.9	59
74	MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials, 2019, 20, 263.	0.7	58
75	Delivery to the Central Nervous System of a Nonreplicative Herpes Simplex Type 1 Vector Engineered with the Interleukin 4 Gene Protects Rhesus Monkeys from Hyperacute Autoimmune Encephalomyelitis. Human Gene Therapy, 2001, 12, 905-920.	1.4	57
76	Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. Arthritis Research, 2004, 7, R256.	2.0	56
77	Exploring Alzheimer's disease mouse brain through X-ray phase contrast tomography: From the cell to the organ. NeuroImage, 2019, 184, 490-495.	2.1	56
78	B-cell differentiation in the CNS of patients with multiple sclerosis. Autoimmunity Reviews, 2005, 4, 549-554.	2.5	54
79	Costs and quality of life of multiple sclerosis in Italy. European Journal of Health Economics, 2006, 7, 45-54.	1.4	54
80	Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. EBioMedicine, 2022, 80, 104042.	2.7	54
81	Immunotherapy for neurological diseases. Clinical Immunology, 2008, 128, 294-305.	1.4	51
82	Stem cell transplantation in multiple sclerosis. Current Opinion in Neurology, 2010, 23, 218-225.	1.8	50
83	Regulation of Human Mesenchymal Stem Cell Functions by an Autocrine Loop Involving NAD⁺Release and P2Y11-Mediated Signaling. Stem Cells and Development, 2011, 20, 1183-1198.	1.1	50
84	Patient adherence to and tolerability of self-administered interferon Î²-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC Neurology, 2012, 12, 7.	0.8	50
85	Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Multiple Sclerosis Journal, 2000, 6, 192-193.	1.4	49
86	Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience. Current Drug Targets, 2013, 14, 637-643.	1.0	48
87	Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurology, 2014, 14, 65.	0.8	47
88	Dramatic rebounds of MS during pregnancy following fingolimod withdrawal. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e377.	3.1	46
89	IFN-Î³ orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of rapamycin pathways. Journal of Allergy and Clinical Immunology, 2017, 139, 1667-1676.	1.5	46
90	Towards Clinical Application of Mesenchymal Stem Cells for Treatment of Neurological Diseases of the Central Nervous System. Journal of NeuroImmune Pharmacology, 2013, 8, 1062-1076.	2.1	45

#	Article	IF	Citations
91	Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study. Multiple Sclerosis Journal, 2015, 21, 1423-1430.	1.4	45
92	Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. Journal of Neurology, 2016, 263, 1727-1735.	1.8	45
93	Quantitative Assessment of Finger Motor Impairment in Multiple Sclerosis. PLoS ONE, 2013, 8, e65225.	1.1	44
94	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsingâ€“remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). Journal of Neurology, 2017, 264, 2436-2449.	1.8	44
95	Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. Neurological Sciences, 2011, 32, 1223-1231.	0.9	43
96	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. Journal of Neurology, 2018, 265, 2851-2860.	1.8	43
97	Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential. Immunity, 2021, 54, 1543-1560.e6.	6.6	42
98	Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Lancet Neurology, The, 2021, 20, 917-929.	4.9	42
99	Is there a role for mesenchymal stem cells in autoimmune diseases?. Autoimmunity, 2008, 41, 592-595.	1.2	41
100	Reward responsiveness and fatigue in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 233-240.	1.4	41
101	Quantitative 3D investigation of Neuronal network in mouse spinal cord model. Scientific Reports, 2017, 7, 41054.	1.6	40
102	Immunological patterns identifying disease course and evolution in multiple sclerosis patients. Journal of Neuroimmunology, 2005, 165, 192-200.	1.1	38
103	Treatment of multiple sclerosis with rituximab: A multicentric Italianâ€“Swiss experience. Multiple Sclerosis Journal, 2020, 26, 1519-1531.	1.4	38
104	Central and peripheral nervous system complications following allogeneic bone marrow transplantation. European Journal of Neurology, 2001, 8, 77-80.	1.7	37
105	Primary varicella zoster infection associated with fingolimod treatment. Neurology, 2011, 76, 1023-1024.	1.5	36
106	Effect of radial shock wave therapy on pain and muscle hypertonia: a double-blind study in patients with multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 622-629.	1.4	36
107	Neurological Complications and Noninvasive Multimodal Neuromonitoring in Critically Ill Mechanically Ventilated COVID-19 Patients. Frontiers in Neurology, 2020, 11, 602114.	1.1	36
108	Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. Neurology, 2021, 96, .	1.5	36

#	Article	IF	Citations
109	Cingulum bundle alterations underlie subjective fatigue in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 442-447.	1.4	34
110	IFNÎ² enhances mesenchymal stromal (Stem) cells immunomodulatory function through STAT1-3 activation and mTOR-associated promotion of glucose metabolism. Cell Death and Disease, 2019, 10, 85.	2.7	34
111	COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments. Multiple Sclerosis Journal, 2021, 27, 2126-2136.	1.4	34
112	Characterization of the TCRB chain repertoire in the New World monkey Callithrix jacchus. Journal of Immunology, 1997, 158, 1201-7.	0.4	34
113	Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice. PLoS ONE, 2019, 14, e0213508.	1.1	33
114	Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon Î²-1b. Neurological Sciences, 2009, 30, 21-31.	0.9	32
115	Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation. Multiple Sclerosis Journal, 2018, 24, 1133-1137.	1.4	32
116	Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. Neurological Sciences, 2011, 32, 181-182.	0.9	31
117	Mechanisms of the adaptive immune response inside the central nervous system during inflammatory and autoimmune diseases. , 2006, 111, 555-566.		30
118	Relapses After Treatment With Rituximab in a Patient With Multiple Sclerosis and Antiâ€“Myelin-Associated Glycoprotein Polyneuropathy. Archives of Neurology, 2007, 64, 1531.	4.9	30
119	Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption. Multiple Sclerosis Journal, 2013, 19, 1236-1237.	1.4	30
120	Tailoring B cell depletion therapy in MS according to memory B cell monitoring. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	30
121	Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. Journal of NeuroImmune Pharmacology, 2012, 7, 665-672.	2.1	29
122	Intrathecal Soluble HLA-E Correlates with Disease Activity in Patients with Multiple Sclerosis and may Cooperate with Soluble HLA-G in the Resolution of Neuroinflammation. Journal of NeuroImmune Pharmacology, 2013, 8, 944-955.	2.1	29
123	Teriflunomide treatment reduces B cells in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e403.	3.1	28
124	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. Neurology, 2020, 95, e1027-e1040.	1.5	28
125	Sirt6 regulates dendritic cell differentiation, maturation, and function. Aging, 2016, 8, 34-47.	1.4	28
126	A RCT Comparing Specific Intensive Cognitive Training to Aspecific Psychological Intervention in RRMS: The SMICT Study. Frontiers in Neurology, 2015, 5, 278.	1.1	27

#	Article	IF	Citations
127	Fulminant Hepatitis Associated With Echovirus 25 During Treatment With Ocrelizumab for Multiple Sclerosis. JAMA Neurology, 2019, 76, 866.	4.5	27
128	Sirt6 inhibition delays the onset of experimental autoimmune encephalomyelitis by reducing dendritic cell migration. Journal of Neuroinflammation, 2020, 17, 228.	3.1	27
129	Autologous Stem Cell Transplantation for Severe Autoimmune Diseases: A 10-Year Experience. Annals of the New York Academy of Sciences, 2007, 1110, 455-464.	1.8	26
130	Th17 Cells in Multiple Sclerosis Express Higher Levels of JAK2, Which Increases Their Surface Expression of IFN-Î³R2. Journal of Immunology, 2012, 188, 1011-1018.	0.4	26
131	CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis. Journal of Clinical Medicine, 2020, 9, 1450.	1.0	26
132	Autoantibody Diagnostics in Neuroimmunology: Experience From the 2018 Italian Neuroimmunology Association External Quality Assessment Program. Frontiers in Neurology, 2019, 10, 1385.	1.1	26
133	Conventional Perimetry, Short-Wavelength Automated Perimetry, Frequency-Doubling Technology, and Visual Evoked Potentials in the Assessment of Patients with Multiple Sclerosis. European Journal of Ophthalmology, 2005, 15, 730-738.	0.7	25
134	CCL5-glutamate interaction in central nervous system: Early and acute presynaptic defects in EAE mice. Neuropharmacology, 2013, 75, 337-346.	2.0	25
135	NG2, a common denominator for neuroinflammation, bloodâ€“brain barrier alteration, and oligodendrocyte precursor response in EAE, plays a role in dendritic cell activation. Acta Neuropathologica, 2016, 132, 23-42.	3.9	25
136	Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. Neurological Sciences, 2017, 38, 53-59.	0.9	25
137	Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population. CNS Drugs, 2020, 34, 425-432.	2.7	25
138	Biological markers of the inflammatory phase of multiple sclerosis. Neurological Sciences, 2003, 24, s271-s274.	0.9	24
139	Systemic Administration of Mesenchymal Stem Cells Increases Neuron Survival after Global Cerebral Ischemia In Vivo (2VO). Neural Plasticity, 2010, 2010, 1-5.	1.0	24
140	Tocilizumab in MOG-antibody spectrum disorder: a case report. Multiple Sclerosis and Related Disorders, 2019, 27, 312-314.	0.9	24
141	COVID-19-related and not related Guillain-BarrÃ© syndromes share the same management pitfalls during lock down: The experience of Liguria region in Italy. Journal of the Neurological Sciences, 2020, 418, 117114.	0.3	24
142	Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2019, 36, 101430.	0.9	23
143	Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e596.	3.1	23
144	COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial. Frontiers in Immunology, 2021, 12, 704110.	2.2	22

#	Article	IF	Citations
145	Antibodies against Epsteinâ€“Barr virus and herpesvirus type 6 are associated with the early phases of Multiple Sclerosis. Journal of Neuroimmunology, 2007, 192, 184-185.	1.1	21
146	Retinal nerve fibre layer measurements and optic nerve head analysis in multiple sclerosis patients. Eye, 2009, 23, 407-412.	1.1	21
147	Contact with the bone marrow microenvironment readdresses the fate of transplanted hematopoietic stem cells. Experimental Hematology, 2010, 38, 968-977.	0.2	21
148	Mesenchymal Stem Cells for Multiple Sclerosis: Does Neural Differentiation Really Matter?. Current Stem Cell Research and Therapy, 2011, 6, 69-72.	0.6	21
149	Human mesenchymal stem cells target adhesion molecules and receptors involved in T cell extravasation. Stem Cell Research and Therapy, 2015, 6, 245.	2.4	21
150	Aggressive multiple sclerosis (2): Treatment. Multiple Sclerosis Journal, 2020, 26, 1045-1063.	1.4	21
151	Neuroinflammation induces synaptic scaling through IL-1Î²-mediated activation of the transcriptional repressor REST/NRSF. Cell Death and Disease, 2021, 12, 180.	2.7	21
152	Charcot-Marie-Tooth (CMT) 1a duplication at 17p11.2 in Italian families. Journal of Medical Genetics, 1992, 29, 492-3.	1.5	20
153	Acute desipramine restores presynaptic cortical defects in murine experimental autoimmune encephalomyelitis by suppressing central <scp>CCL</scp>5 overproduction. British Journal of Pharmacology, 2014, 171, 2457-2467.	2.7	19
154	Hereditary motor and sensory neuropathy with myelin outfolding: Clinical, genetic and neuropathological study of three cases. Journal of the Neurological Sciences, 1994, 122, 20-27.	0.3	18
155	A restricted T cell response to myelin basic protein (MBP) is stable in multiple sclerosis (MS) patients. Clinical and Experimental Immunology, 1998, 111, 186-192.	1.1	18
156	Different MRI patterns in MS worsening after stopping fingolimod. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e566.	3.1	18
157	Aggressive multiple sclerosis: a singleâ€centre, realâ€world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab. European Journal of Neurology, 2020, 27, 2047-2055.	1.7	18
158	High or increasing serum NfL is predictive of impending multiple sclerosis relapses. Multiple Sclerosis and Related Disorders, 2022, 59, 103535.	0.9	18
159	Induction of experimental autoimmune encephalomyelitis in rats and immune response to myelin basic protein in lipid-bound form. Journal of the Neurological Sciences, 1993, 119, 91-98.	0.3	17
160	Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. Neurological Sciences, 2005, 26, s200-s203.	0.9	17
161	Antiâ€Glutamic Acid Decarboxylase Limbic Encephalitis Without Epilepsy Evolving Into Dementia With Cerebellar Ataxia. Archives of Neurology, 2012, 69, 1064-6.	4.9	17
162	Impact of treatment on cellular immunophenotype in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	17

#	Article	IF	Citations
163	Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis. Neurotherapeutics, 2021, 18, 2579-2588.	2.1	17
164	Investigation of paroxysmal dystonia in a patient with multiple sclerosis: A transcranial magnetic stimulation study. Clinical Neurophysiology, 2008, 119, 63-70.	0.7	16
165	Selective impairments of motor sequence learning in multiple sclerosis patients with minimal disability. Brain Research, 2014, 1585, 91-98.	1.1	16
166	In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma. Immunology Letters, 2017, 181, 109-115.	1.1	16
167	17p11.2 Duplication Is a Common Finding in Sporadic Cases of Charcot-Marie-Tooth Type 1. European Neurology, 1994, 34, 135-139.	0.6	15
168	Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial. Frontiers in Behavioral Neuroscience, 2016, 10, 28.	1.0	15
169	Characterization of mouse spinal cord vascular network by means of synchrotron radiation X-ray phase contrast tomography. Physica Medica, 2016, 32, 1779-1784.	0.4	15
170	Ecological impact of isolated cognitive relapses in MS. Multiple Sclerosis Journal, 2020, 26, 114-117.	1.4	15
171	Neuroprotective Potential of Dendritic Cells and Sirtuins in Multiple Sclerosis. International Journal of Molecular Sciences, 2022, 23, 4352.	1.8	15
172	Autologous haematopoietic stem-cell transplantation in multiple sclerosis: benefits and risks. Neurological Sciences, 2009, 30, 175-177.	0.9	14
173	Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 1859-1870.	1.4	14
174	Neurorepair with mesenchymal stem cells: hope or hype?. Lancet Neurology, The, 2012, 11, 123-125.	4.9	13
175	Mesenchymal stem cells exert a remarkable regenerative effect requiring minimal CNS integration. Experimental Neurology, 2013, 247, 292-295.	2.0	13
176	Pediatric optic neuritis and anti MOG antibodies: a cohort of Italian patients. Multiple Sclerosis and Related Disorders, 2020, 39, 101917.	0.9	13
177	MiRâ€142â€3p regulates synaptopathyâ€driven disease progression in multiple sclerosis. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	13
178	EAE in the common marmoset Callithrix jacchus. International MS Journal, 2003, 10, 6-12.	0.3	13
179	Myelin basic protein intramolecular spreading without disease progression in a patient with multiple sclerosis. Journal of Neuroimmunology, 2000, 110, 240-243.	1.1	12
180	Alterations of glutamate release in the spinal cord of mice with experimental autoimmune encephalomyelitis. Journal of Neurochemistry, 2010, 115, 343-352.	2.1	12

#	Article	IF	Citations
181	X-ray Phase Contrast Tomography Serves Preclinical Investigation of Neurodegenerative Diseases. Frontiers in Neuroscience, 2020, 14, 584161.	1.4	12
182	Restricted immune responses lead to CNS demyelination and axonal damage. Journal of Neuroimmunology, 2000, 107, 178-183.	1.1	11
183	Immuno-Therapeutic Potential of Haematopoietic and Mesenchymal Stem Cell Transplantation in MS. Results and Problems in Cell Differentiation, 2009, 51, 237-257.	0.2	11
184	Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. BMC Neurology, 2014, 14, 103.	0.8	10
185	Mesenchymal stromal cells and immunity: Introductory overview. Immunology Letters, 2015, 168, 127-128.	1.1	10
186	CSF oligoclonal bands and normal appearing white matter periventricular damage in patients with clinically isolated syndrome suggestive of MS. Multiple Sclerosis and Related Disorders, 2019, 31, 93-96.	0.9	10
187	Corneal epithelial dendritic cells in patients with multiple sclerosis: An in vivo confocal microscopy study. Journal of Clinical Neuroscience, 2020, 81, 139-143.	0.8	10
188	Different Susceptibility of T and B Cells to Cladribine Depends On Their Levels of Deoxycytidine Kinase Activity Linked to Activation Status. Journal of NeuroImmune Pharmacology, 2022, 17, 195-205.	2.1	10
189	Hydroxycarboxylic Acid Receptor 2, a Pleiotropically Linked Receptor for the Multiple Sclerosis Drug, Monomethyl Fumarate. Possible Implications for the Inflammatory Response. Frontiers in Immunology, 2021, 12, 655212.	2.2	10
190	Characterization of the response to myelin basic protein in a non human primate model for multiple sclerosis. European Journal of Immunology, 2001, 31, 474-479.	1.6	9
191	Guillainâ€“BarrÃ© Syndrome after Reactivation of Varicellaâ€“Zoster Virus. New England Journal of Medicine, 2001, 344, 65-66.	13.9	9
192	Adult stem cells for spinal cord injury: what types and how do they work?. Cytotherapy, 2008, 10, 541-542.	0.3	9
193	Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report. Multiple Sclerosis and Related Disorders, 2018, 26, 52-54.	0.9	9
194	Mesenchymal stem cells instruct a beneficial phenotype in reactive astrocytes. Glia, 2021, 69, 1204-1215.	2.5	9
195	A case of thyroiditis during natalizumab therapy for multiple sclerosis. Journal of Endocrinological Investigation, 2011, 34, 408-409.	1.8	8
196	Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS. Multiple Sclerosis Journal, 2018, 24, 623-631.	1.4	8
197	Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e695.	3.1	8
198	Stem cells for multiple sclerosis: promises and reality. Regenerative Medicine, 2007, 2, 7-9.	0.8	7

#	Article	IF	Citations
199	Multiple sclerosis and non-communicating syringomyelia: a casual association or linked diseases?. Acta Neurologica Scandinavica, 1999, 100, 270-273.	1.0	7
200	Could arterial spin labelling perfusion imaging uncover the invisible in Nâ€methylâ€<scp>d</scp>â€aspartate receptor encephalitis?. European Journal of Neurology, 2019, 26, e86-e87.	1.7	7
201	Intravenous immunoglobulin, plasmalymphocytapheresis and azathioprine in chronic progressive multiple sclerosis. Italian Journal of Neurological Sciences, 1994, 15, 49-53.	0.1	6
202	Differential display analysis of murine encephalitogenic mRNA.. International Immunology, 1998, 10, 1819-1823.	1.8	6
203	18F-Fluorodeoxyglucose Positron Emission Tomography Tracks the Heterogeneous Brain Susceptibility to the Hyperglycemia-Related Redox Stress. International Journal of Molecular Sciences, 2020, 21, 8154.	1.8	6
204	Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients. Multiple Sclerosis Journal, 2022, 28, 1937-1943.	1.4	6
205	A Single Nucleotide ADA Genetic Variant Is Associated to Central Inflammation and Clinical Presentation in MS: Implications for Cladribine Treatment. Genes, 2020, 11, 1152.	1.0	5
206	Ghost spasticity in multiple sclerosis. Journal of Electromyography and Kinesiology, 2020, 51, 102408.	0.7	5
207	Assessing upper limb function in multiple sclerosis using an engineered glove. European Journal of Neurology, 2020, 27, 2561-2567.	1.7	4
208	Degree of microstructural changes within T1-SE versus T1-GE hypointense lesions in multiple sclerosis: relevance for the definition of â€œblack holesâ€. European Radiology, 2020, 30, 3843-3851.	2.3	4
209	Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus. Journal of Neurology, 2021, 268, 1540-1543.	1.8	4
210	Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis. , 2013, , 433-455.		4
211	Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study. CNS Drugs, 2022, 36, 83-96.	2.7	4
212	Choroidal Thickness in Multiple Sclerosis: An Optical Coherence Tomography Study. Journal of		

#	Article	IF	Citations
217	A bridge between evidence-based laboratory diagnostics and research in neuroimmunology: why standardizations and guidelines matter. Neurological Sciences, 2017, 38, 213-216.	0.9	2
218	Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Multiple Sclerosis Journal, 2000, 6, 192-193.	1.4	2
219	Animal Models of Demyelination of the Central Nervous System. , 1999, , 233-245.		2
220	A major influence of the T cell receptor repertoire as compared to antigen processingâ€“presentation in the selection of myelin basic protein epitopes in multiple sclerosis. Journal of Neuroimmunology, 1999, 96, 241-244.	1.1	1
221	Can we kill an extra bird with the same stone?. Inflammatory Bowel Diseases, 2011, 17, E124-E125.	0.9	1
222	Bone Marrow Transfer in Relapsing-Remitting EAE Ameliorates Disease at First Remission, with No Synergistic Effect upon Co-Transplantation with Mesenchymal Stem Cells. Vaccines, 2021, 9, 736.	2.1	1
223	Characterization of the response to myelin basic protein in a non human primate model for multiple sclerosis. European Journal of Immunology, 2001, 31, 474-9.	1.6	1
224	Interindividual Variability of Cranioencephalic Relationships as Predicted by CT. Journal of Computer Assisted Tomography, 1991, 15, 647-654.	0.5	0
225	Circulating Lymphocyte Subsets after Total Lymphoid Irradiation in Chronic Progressive Multiple Sclerosis. Annals of the New York Academy of Sciences, 1993, 677, 458-461.	1.8	0
226	Hereditary motor and sensory neuropathy with myelin outfolding: Clinical, genetic and neuropathological study of three cases. Journal of the Neurological Sciences, 1994, 125, 215.	0.3	0
227	OR.82. Mesenchymal Stem Cells Treat CNS Autoimmunity Through a Dual Effect On Inflammation and Tissue Damage. Clinical Immunology, 2006, 119, S35.	1.4	0
228	Neuropathological Advances in Multiple Sclerosis. , 2007, , 3-9.		0
229	FP17-TU-06 Th17, an effector T lymphocyte subset associated with multiple sclerosis (MS) relapses: antigen specificity, cytokine production, and sensitivity to interferon (IFN)-Î². Journal of the Neurological Sciences, 2009, 285, S84.	0.3	0
230	10 Mesenchymal stem cells as a strategy for the treatment of multiple sclerosis and other diseases of the central nervous system. , 2013, , 185-210.		0
231	Unraveling the regulatory role of NK cells on T-cell effector functions: Implications for CNS autoimmunity. Journal of Neuroimmunology, 2014, 275, 54-55.	1.1	0
232	Do NK cells play a role in the possible association between natalizumab treatment and the development of melanoma?. Journal of Neuroimmunology, 2014, 275, 218.	1.1	0
233	Bone marrow mesenchymal stem cell-derived secreted factors promote the proliferation of adult subventricular zone-neural stem cells and foster their stemness in vitro under pathogenic conditions. Journal of Neuroimmunology, 2014, 275, 195.	1.1	0
234	Analysis of the interferon gamma modulated pathways related to the therapeutic plasticity of bone marrow-derived mesenchymal stem cells through a SILAC-based proteomic approach. Journal of Neuroimmunology, 2014, 275, 191-192.	1.1	0

#	Article	IF	Citations
235	Lack of NG2 expression on immune cells and oligodendrocytes progenitor cells modulates EAE phenotype. Journal of Neuroimmunology, 2014, 275, 148-149.	1.1	0
236	Possible role of miRNAs in the modulation of neuroinflammation by mesenchymal stem cells. Journal of Neuroimmunology, 2014, 275, 150.	1.1	0
237	Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE.. Blood, 2009, 114, 4732-4732.	0.6	0
238	Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience. Current Drug Targets, 2013, 999, 1-6.	1.0	0
239	Experimental autoimmune encephalomyelitis in the common marmoset Callithrix jacchus. , 1999, , 79-84.		0
240	Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No. Multiple Sclerosis Journal, 2022, 28, 1326-1328.	1.4	0